OraSure Corp (OSUR) - Long-Term Liabilities to Capital

OraSure Corp - graphic logo of issuer OSUR

The stability of OraSure Technologies (OSUR) is underpinned by patents for rapid tests and close ties to the public healthcare sector. Demand for genetic research remains largely independent of economic crises, although sales of consumables may fluctuate. This price chart, where the indicator stands at 0.05, reflects the dynamics of a leader in the development of mobile software and next-generation molecular diagnostic systems.

OraSure - OSUR Long-Term Debt to Capital (period 07/04/2022 - 10/30/2026)

Comprehensive metric breakdowns and analytics for OraSure Technologies (OSUR)

- stock value and consensus price forecast:
Stock Quotes OraSure Technologies, Inc.|OSUR - Analyst Consensus Forecast
- market capitalization indicators:
Market Value OraSure Technologies|OSUR - Enterprise Value
- book value of equity indicators:
Equity per Share OraSure|OSUR - Book Capitalization|Market Capitalization to Book Value Ratio orasure.com|OSUR - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Ratio OraSure Technologies|OSUR - Long-Term Debt to Capital|Short-Term Debt to Capital orasure.com|OSUR - Company Debts|Debt to Book Capitalization Ratio OraSure Technologies|OSUR - Company Long-Term Liabilities|Short-Term Debt OraSure|Interim Coverage Ratio orasure.com
- financial results and valuation multiples details:
OSUR - Net Profit
Comprehensive company analysis:OraSure Technologies, Inc.
Product sample of OraSure Technologies

OraSure Technologies investments in the democratization of home diagnostics require a balance between capital expenditures and debt load, which is reflected in the dynamics of long-term loans to equity. This indicator compares obligations with a maturity of more than one year against net assets, allowing for an assessment of the degree of financial leverage and the stability of the capital structure while scaling innovative DNA collection systems.

Competing companies

Long-Term Debt to Equity Ratio Agilent Technologies, Inc. (A)|Long-Term Debt to Capital DGX|ILMN - Long-Term Liabilities to Capital|Long-Term Debt to Capital EXAS (Exact Sciences)|RVTY: Long-Term Debt to Capital Ratio|Bio-Rad - Long-Term Debt to Capital|NNNN - Long-Term Debt to Capital|Sterigenics (SHC) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio QDEL|OPK (OPKO Health, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital CareDx Corp|Long-Term Debt to Equity Maravai LifeSciences Holdings, Inc. (MRVI)|Long-Term Debt to Equity FLGT (Fulgent Genetics Inc)|Fluidigm - Long-Term Debt to Equity Ratio|Cytek Corp (CTKB) - Long-Term Liabilities to Capital|XGN - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital mdxhealth.com MDXH|LUCD: Long-Term Debt to Capital|PRE - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Insight Molecular Diagnostics, Inc.|Trinity Biotech Corp (TRIB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ProPhase Labs, Inc. (PRPH)|AIMD - Long-Term Liabilities to Capital|Long-Term Debt to Equity Co-Diagnostics CODX|Long-Term Debt to Capital Coefficient HSCS|Biomerica, Inc - Long-Term Debt to Capital|CDIO - Long-Term Debt to Capital|Virax Biolabs Group (VRAX) - Long-Term Debt to Equity|BJDX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio AWH|Long-Term Debt to Capital Accelerate Diagnostics Inc.|Long-Term Debt to Equity CENTOGENE, N.V. (CNTG)|ENZ (enzo.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital FRES (Fresh2 Group)|Genetic Technologies Ltd (GENE) - Long-Term Liabilities to Capital|ME: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient PMD (Psychemedics Corp.)